Cash cost of the wait: management is funding a defined waiting period whose end is already scheduled
The model's full reasoning — Q3 2018 call → NOThe question asks whether management describes the company as currently living through a defined waiting period it is paying for out of its own pocket — with three specific conditions. Let me analyze the transcript carefully. (1) THE COMPANY IS PAYING NOW FOR SOMETHING NOT YET EARNING. Looking for real resources currently being consumed with nothing yet coming back. - The sales force expansion for ARISTADA: "During the fourth quarter, we will further expand our field and hospital-based sales force by approximately 50 sales representatives based on the opportunities we are identifying and the encouraging trends that we are seeing." — This is future, not current, and it's for an already-launched product. - For 5461: "we've done enormous amount of preparation for launch of 5461, but we won't pull the trigger on hiring the next level of sales force expansion until such time as we really have a sense that the drug is going to be approved." — So they are NOT paying for the sales force yet. They're explicitly deferring it. - For 3831: "we continue to engage in the necessary work to support future commercial opportunities in psychiatry as we prepare for the regulatory decision of ALKS 5461 for major depressive disorder and pivotal data for ALKS 3831 for schizophrenia." — This is preparation, but not described as a current cost landing in results. - R&D expenses: "Our investment in SG&A decreased slightly compared to the second quarter, primarily driven by the timing of launch activities for ARISTADA INITIO in Q2." — ARISTADA INITIO is already launched. - The company's expenses are described as "investments in the commercial organization in support of VIVITROL and ARISTADA" — these are for already-launched products earning revenue. - For 4230: "we're in the process of implementing the protocol amendment... expect to reopen enrollment of the fifth cohort next month" — this is R&D, but it's not described as a "waiting period" with a near-dated earning event. (2) MANAGEMENT SPEAKS AS THOUGH THE WAIT IS THE COMPANY'S MAIN CURRENT WORK. The main current work seems to be preparing for the 5461 AdCom (November 1) and the 3831 data readout (Q4). But these are regulatory/data events, not a "paying now for something not yet earning" situation. The company is not carrying a cost for these — they're R&D programs in development.
| Ticker | Company | Call | Date | Call grade |
|---|---|---|---|---|
| KOPN | Kopin Corporation | Q4 2023 | 2024-03-14 | C+ |
| LILA | Liberty Latin America Ltd. | Q4 2023 | 2024-02-23 | C |
| SBS | Companhia de Saneamento Básico do Estado | Q3 2023 | 2023-11-10 | C+ |
| QTRX | Quanterix Corporation | Q3 2023 | 2023-11-07 | B |
| APPS | Digital Turbine, Inc. | Q1 2024 | 2023-08-08 | D |
| PRPH | ProPhase Labs, Inc. | Q1 2023 | 2023-05-11 | F |
| CDE | Coeur Mining, Inc. | Q1 2023 | 2023-05-11 | C+ |
| SOL | ReneSola Ltd | Q3 2022 | 2022-12-01 | C+ |
| FLL | Full House Resorts, Inc. | Q3 2022 | 2022-11-07 | B |
| EHTH | eHealth, Inc. | Q2 2021 | 2021-07-29 | F |
| IRT | Independence Realty Trust, Inc. | Q2 2018 | 2018-08-02 | B |
| YUM | Yum! Brands, Inc. | Q2 2018 | 2018-08-02 | C |
| IBTX | Independent Bank Group, Inc. | Q3 2017 | 2017-10-24 | A |
| FLEX | Flex Ltd. | Q1 2018 | 2017-07-28 | F |
| DAN | Dana Incorporated | Q1 2017 | 2017-05-02 | B |
SBS · Q3 2023 → YESThe question is whether management describes the company as currently living through a defined waiting period it's paying for out of its own pocket. YES The transcript shows management describing the company as currently bearing real, ongoing cash costs (salaries, consulting, transition work) for the IDP/restructuring program whose benefits (full expense reduction, shared-services center operational) are not yet realized. The far side is a specific, near-dated event: full 3.7% staff reduction and shared-services center operational by mid-2024 (July 2024 for full benefit), with the program already in motion and on schedule. Management frames this as the main current work, not a setback, and treats the costs as self-funded. This meets all three conditions.
EHTH · Q2 2021 → YESThe question is whether management describes the company as currently living through a defined waiting period it is paying for out of its own pocket. YES The transcript shows management describing the company as currently living through a defined waiting period for the AEP, paying for it out of its own pocket through heavy investments in internal agents and quality initiatives. They hired agents early, many still in training with lower productivity, and are bearing the cost of additional training and customer service expansion in Q3. This is framed as a chosen investment to improve enrollment quality and prepare for the fourth-quarter AEP, not an apology or external issue.
YUM · Q2 2018 → YESThe question is whether management describes the company as currently living through a defined waiting period it is paying for out of its own pocket. YES The transcript shows management describing a clear, self-funded transition cost tied to the refranchising effort. They explicitly call out the “timing mismatch between G&A savings and refranchising” as one of the four items weighing on Q2 core operating profit, and they quantify the full-year headwind at 6 7 percentage points. This is presented as a real, ongoing drag on current results while they complete the shift to 98 % franchised by year-end 2018 and reach the 1.7 % G&A run-rate target in 2019.